Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of CRD-4730 in adults with catecholaminergic polymorphic ventricular tachycardia
NL-OMON58910Phase 2Recruiting
- Sponsor
- Cardurion Pharmaceuticals
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of CRD-4730 in catecholaminergic polymorphic ventricular tachycardia (CPVT), sponsored by Cardurion Pharmaceuticals. Primary endpoint: Treatment-emergent adverse events related to study drug. Started Nov 2025; status: recruiting.
02
Drugs
CRD-4730
03
Conditions
catecholaminergic polymorphic ventricular tachycardia (CPVT)
Beyond the preview
Go deeper on NL-OMON58910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58910.